Bosentan, 99%, a endothelin (ET) receptor antagonist

Name: Bosentan, 99%, a endothelin (ET) receptor antagonist | 147536-97-8
Brand: J&K Chemical
SKU: JK524508_10_MG
Price: 38.9 USD
Availability: InStock

Cat. No JK524508_10_MG

Vendor: J&K Chemical

Product Information

Product Name

Bosentan, 99%, a endothelin (ET) receptor antagonist

Brand Name

J&K

Product Number

524508

CAS

147536-97-8

SDS Document

View/Download

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

104865

IUPAC Name

4-tert-butyl-N-6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-ylbenzenesulfonamide

InChI Key

GJPICJJJRGTNOD-UHFFFAOYSA-N

SMILES

CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC

Safety Information

Storage Condition

Freezer -20℃

References Data Source From Pubchem

Pharmacokinetics, Safety Profile, and Tolerability of MN-08 Tablets after Single and Multiple Ascending Doses in Healthy Chinese Volunteers

Publication Name: Clinical Drug Investigation

Publication Date: 2026-02-25

DOI: 10.1007/s40261-026-01522-6

Prevalence of substances with OATP1B1 inhibitory properties in individual case safety reports of suspected statin-associated myopathy – an analysis of Swiss pharmacovigilance data

Publication Name: European Journal of Clinical Pharmacology

Publication Date: 2026-02-24

DOI: 10.1007/s00228-025-03968-7

Silver nanoparticles-based green fluorescent probe for determination of Bosentan in pharmaceutical formulation and spiked plasma samples

Publication Name: BMC Chemistry

Publication Date: 2026-02-21

DOI: 10.1186/s13065-026-01737-w

Results of a pulmonary hypertension screening program for premature infants with bronchopulmonary dysplasia

Publication Name: Journal of perinatology : official journal of the California Perinatal Association

Publication Date: 2026-02-16

DOI: 10.1038/s41372-026-02580-6

Predicting pulmonary hypertension in infants with bronchopulmonary dysplasia

Publication Name: Journal of perinatology : official journal of the California Perinatal Association

Publication Date: 2026-02-16

DOI: 10.1038/s41372-026-02576-2

Bosentan, 99%, a endothelin (ET) receptor antagonist

Product Information

General Information

Safety Information

References Data Source From Pubchem

Pharmacokinetics, Safety Profile, and Tolerability of MN-08 Tablets after Single and Multiple Ascending Doses in Healthy Chinese Volunteers

Prevalence of substances with OATP1B1 inhibitory properties in individual case safety reports of suspected statin-associated myopathy – an analysis of Swiss pharmacovigilance data

Silver nanoparticles-based green fluorescent probe for determination of Bosentan in pharmaceutical formulation and spiked plasma samples

Results of a pulmonary hypertension screening program for premature infants with bronchopulmonary dysplasia

Predicting pulmonary hypertension in infants with bronchopulmonary dysplasia